Clinical biomarkers directing the management of patients with colon and lung cancer (beyond oncogene-addicted NSCLC)
Treatment personalisation plays a key role in the current management of patients with cancer. Several biomarkers have shown clinical utility and may guide therapeutic decisions. Amongst patients with lung cancer, the level of expression of programmed death ligand 1 (PD-L1) has both prognostic and pr...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2020-09-01
|
| Series: | Forum of Clinical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/fco-2019-0014 |